Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: A review. JAMA. 2018; 320: 1360-1372.
Alghasham A and Rasheed Z. Therapeutic targets for rheumatoid arthritis: Progress and promises. Autoimmunity. 2014; 47: 77-94.
Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008; 48: 303-332.
Cao YJ, Sawamoto T, Valluri U, Cho K, Lewand M, Swan S, Lasseter K, Matson M, Holman J Jr, Keirns J, Zhu T. Pharmacokinetics, pharmacodynamics, and safety of ASP015K (Peficitinib), a new Janus kinase inhibitor, in healthy subjects. Clin Pharmacol Drug Dev. 2016; 5: 435-449.
Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001; 69: 169-174.
Doogue MP and Polasek TM. The ABCD of clinical pharmacokinetics. Ther Adv Drug Saf. 2013; 4: 5-7.
European Medicines Agency. Guideline on the investigation of drug interactions. 2013. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline- investigation-drug-interactions-revision-1_en.pdf
Fatimah N, Salim B, Nasim A, Hussain K, Gul H, Niazi S. Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire). Clin Rheumatol. 2016; 35: 1341-1345.
Food and Drug Administration. Clinical Pharmacology1: Phase 1 Studies and Early Drug Development. https://www.fda.gov/media/84920/download
Food and Drug Administration. Guidance for Industry Assessing the Effects of Food on Drugs in INDs and NDAs — Clinical Pharmacology Considerations. 2019. https://www.fda.gov/media/121313/download
Food and Drug Administration. Guidance for Industry Clinical Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. 2016. https://www.fda.gov/media/134581/download
Food and Drug Administration. Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. 2003. https://www.fda.gov/media/71311/download
Food and Drug Administration. Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing and Labeling. 2020. https://www.fda.gov/media/78573/download
Food and Drug Administration. Guidance for Industry and Food and Drug Administration Staff Collection of Race and Ethnicity Data. 2016. https://www.fda.gov/media/75453/download
Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012; 22: 820-827.
Ito M, Yamazaki S, Yamagami K, Kuno M, Morita Y, Okuma K, Nakamura K, Chida N, Inami M, Inoue T, Shirakami S, Higashi Y. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci. 2017; 133: 25-33.
Jegatheeswaran J, Turk M, Pope JE. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. Immunotherapy. 2019; 11: 737-754.
Lentz KA. Current methods for predicting human food effect. AAPS J. 2008; 10: 282- 288.
Liang X, Giacomini KM. Transporters involved in metformin pharmacokinetics and treatment response. J Pharm Sci. 2017; 106: 2245-2250.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New Engl J Med. 2011; 365: 2205-2219.
Migita K, Izumi Y, Torigoshi T, Satomura K, Izumi M, Nishino Y, Jiuchi Y, Nakamura M, Kozuru H, Nonaka F, Eguchi K, Kawakami A, Motokawa S. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. Clin Exp Immunol. 2013; 174: 356-363.
Miyatake D, Shibata T, Toyoshima J, Kaneko Y, Oda K, Nishimura T, Katashima M, Sakaki M, Inoue K, Ito T, Uchida N, Furihata K, Urae A. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function. Clin Pharmacol Drug Dev. 2020a; 9: 699-708.
Miyatake D, Shibata T, Shibata M, Kaneko Y, Oda K, Nishimura T, Katashima M, Sekino H, Furihata K, Urae A. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function. Clin Drug Investig. 2020b; 40: 149-159.
Nelson E. Kinetics of drug absorption, distribution, metabolism, and excretion. J Pharm Sci. 1961; 50: 181-192.
Oda K, Cao YJ, Sawamoto T, Nakada N, Fisniku O, Nagasaka Y, Sohda KY. Human mass balance, metabolite profile and identification of metabolic enzymes of [¹⁴C]ASP015K, a novel oral janus kinase inhibitor. Xenobiotica. 2015; 45: 887-902.
O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004; 350: 2591-2602.
Olafuyi O, Parekh N, Wright J, Koenig J. Inter-ethnic differences in pharmacokinetics- is there more that unites than divides? Pharmacol Res Perspect. 2021; 9: e00890.
O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013; 72 (Suppl 2): 111-115.
O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol. 2002; 2: 37-45.
O'Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov. 2004; 3: 555-564.
O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012; 36: 542-550.
Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N- acetyltransferase, xanthine oxidase, and CYP1A2. Clin Pharmacol Ther. 1992; 52: 643-658.
Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, Kasuga M, Okumura K. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001; 18: 1400-1404.
Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007; 117: 1422-1431.
Shu Y, Brown C, Castro RA, Shi RJ, Lin ET,Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 2008; 83: 273-280.
Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016; 68: 1-26.
Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016; 75: 3- 15.
Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Shiomi T, Yamada E, van der Heijde D. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019; 78: 1305-1319.
Tanaka Y, Izutsu H. Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. Expert Opin Pharmacother. 2020; 21: 1015-1025.
Tanaka Y, Takeuchi T, Tanaka S, Kawakami A, Iwasaki M, Song YW, Chen YH, Wei JC, Lee SH, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Akazawa R, Shiomi T, Yamada E. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019; 78: 1320-1332.
Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016; 36: 685-695.
Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015; 74: 27-34.
Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017; 13: 234-243.
World Health Organization. Chronic rheumatic conditions. 2020. https://www.who.int/chp/topics/rheumatic/en/
Wu HF, Hristeva N, Chang J, Liang X, Li R, Frassetto L, Benet LZ. Rosuvastatin pharmacokinetics in Asian and White subjects wild-type for both OATP1B1 and BCRP under control and inhibited conditions. J Pharm Sci. 2017; 106: 2751- 2757.
Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2014; 24: 33-40.
Yasuda SU, Zhang L, Huang S-M. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008; 84: 417-423.
Zhu T, Howieson C, Wojtkowski T, Garg JP, Han D, Fisniku O, Keirns J. The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor. Clin Pharmacol Drug Dev. 2017a; 6: 548-555.
Zhu T, Parker B, Wojtkowski T, Nishimura T, Garg JP, Han D, Fisniku O, Keirns J. Drug interactions between peficitinib, an orally administered, once-daily Janus kinase inhibitor, and rosuvastatin in healthy subjects. Clin Pharmacokinet. 2017b; 56: 747-757.
大西 明弘. 高齢者における薬物動態の特徴. Jpn J Clin Pharmacol Ther. 2008; 39: 2-5.
門倉 健. 薬物動態情報に基づいた Precision Medicine の実践と推進に関する研究. 2014. 筑波大学大学院 生命産業科学研究科 生命産業科学専攻 博士論文. https://tsukuba.repo.nii.ac.jp/records/32932
田中良哉. 関節リウマチ治療における新しい標的分子－シグナル阻害低分子化合薬は生物学的製剤を超えるか？－. 炎症と免疫. 2009; 17: 214-218.
中島敦夫. 関節リウマチの治療薬の適応と禁忌， 使い方 抗リウマチ薬 (DMARDs). 内科. 2009; 103: 655-659.
古家英寿, 神田繭子, 今津屋聡子, 松隈京子, 入江伸, 熱田豊, 及川桂史, 門倉健. 臨床医薬. 2007; 23: 755-763.
宮武 大輔. ペフィシチニブの薬物動態における肝および腎機能障害の影響と他剤との差異分析. 2021. 筑波大学大学院 理工情報生命学術院 生命地球科学研究群 生命産業科学学位プログラム 博士論文. https://tsukuba.repo.nii.ac.jp/records/2000855
森和彦. 臨床開発における薬物動態研究－治験相談の経験から－. 薬物動態. 2001; 16: S136-137.
山岡邦宏，田中良哉. Jak3 阻害剤による関節リウマチ治療. リウマチ科. 2008; 40: 526-530.
ICH 医薬品規制調和国際会議. E5 外国臨床データを受け入れる際に考慮すべき民族的要因についての指針. 1998. https://www.pmda.go.jp/files/000156571.pdf
ICH 医薬品規制調和国際会議. E8 臨床試験の一般指針. 1998. https://www.pmda.go.jp/files/000156372.pdf
ICH 医薬品規制調和国際会議. E17 国際共同治験の計画及びデザインに関する一般原則に関するガイドライン. 2018. https://www.pmda.go.jp/files/000224557.pdf
アステラス製薬株式会社. 経口 JAK 阻害剤「スマイラフ®錠」既存治療で効果不十分な関節リウマチ（関節の構造的損傷の防止を含む）治療薬として日本で製造販売承認取得（2019 年 3 月 26 日プレスリリース）. https://www.astellas.com/jp/system/files/news/2019- 03/190326_jp_pefi_approval_final_0.pdf
アステラス製薬株式会社. スマイラフ®錠 50mg／スマイラフ®錠 100mg 添付文書 2021 年 10 月改訂（第 2 版）. https://amn.astellas.jp/content/dam/jp/amn/jp/ja/di/doc/Pdfs/DocNo202110338_y.pdf
アステラス製薬株式会社. スマイラフ®錠 50mg／スマイラフ®錠 100mg インタビューフォーム. 2021 年 10 月改訂（第 7 版）. https://amn.astellas.jp/content/dam/jp/amn/jp/ja/di/doc/Pdfs/DocNo202110340_y.pdf
アステラス製薬株式会社. ペフィシチニブ申請資料概要 平成30 年（2018 年） 5 月 31 日申請. https://www.pmda.go.jp/drugs/2019/P20190419003/index.html
アステラス製薬株式会社. イリボー®錠 2.5μg／イリボー®錠 5μg 添付文書 2021 年 3 月改訂（第 2 版）. https://amn.astellas.jp/content/dam/jp/amn/jp/ja/di/doc/Pdfs/DocNo202109715_y.pdf
ノバルティスファーマ株式会社. タシグナ®カプセル 50mg／タシグナ®カプセル 150mg／タシグナ®カプセル 200mg 添付文書 2020 年 12 月改訂（第 2版）. https://www.drs- net.novartis.co.jp/siteassets/common/pdf/tas/pi/pi_tas_202012.pdf
厚生科学審議会疾病対策部会 リウマチ等対策委員会. 厚生科学審議会疾病対策部会 リウマチ等対策委員会報告書 平成 30 年（2018 年）11 月. https://www.mhlw.go.jp/content/10901000/000377563.pdf
厚生労働省医薬局審査管理課. 医薬品の臨床薬物動態試験について. 平成 13年（2001 年）6 月. https://www.pmda.go.jp/files/000206738.pdf
厚生労働省医薬・生活衛生局医薬品審査管理課. 医薬品開発と適正な情報提供のための薬物相互作用ガイドラインについて. 平成 30 年（2018 年）7 月 23 日. https://www.pmda.go.jp/files/000225191.pdf
厚生労働省医薬・生活衛生局医薬品審査管理課. 後発医薬品の生物学的同等性試験ガイドライン等の一部改正について. 令和 2 年（2020 年）3 月 19 日. https://www.pmda.go.jp/files/000234565.pdf
厚生労働省 健康局 がん・疾病対策課. リウマチ対策の現状について. 平成 30年（2018 年）3 月 26 日. https://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000199523.pdf
論文の公開元へ
